Key points from article :
Discovery of new cardiovascular medicines at lowest point in decades.
Need a more focused medicines approach.
Trials should combine technology and real-world evidence to accelerate development.
Current ecosystem doesn't readily recognize scientifically robust subgroup data.
Payers, regulators, policymakers, and industry need to challenge old paradigms.
